Vivani Medical

VANI · NASDAQ

$1.12+$0.00 (+0.00%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.12

VANI analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $4.72 (+321.2% upside)

Low: $3.54
Now: $1.12
High: $7.35

Upgrades and downgrades

The latest rating actions, newest first

VANI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Lake Street	Jun 23, 2026	Initiates	Buy	$4.00	27%
HC Wainwright & Co.	Mar 31, 2026	Maintains	Buy	$4.00 → $3.50	40%

The case for and against

Updated Feb 9, 2026

Bull case

Vivani Medical Inc. is positioned favorably due to the promising potential of its candidate NPM-139, which could enhance the safety and tolerability of existing therapies such as semaglutide, thereby reducing therapy discontinuation rates. The encouraging clinical data indicating that NPM-139 achieves approximately 20% weight loss sustained over six months further underscores its therapeutic potential and market opportunity. As a preclinical-stage biopharmaceutical company, the advancements in both its Biopharm and Neuromodulation divisions reflect a strong commitment to developing innovative treatments for chronic diseases, contributing to a bullish outlook on its stock.

Bear case

Vivani Medical Inc faces significant risks that contribute to a negative outlook on its stock, particularly surrounding the clinical viability and commercial potential of its lead product, NPM-139. The company's reliance on this product is underscored by multiple potential points of failure: lack of success in clinical trials, difficulties in obtaining regulatory approval, and challenges in capturing market share against competitive pressures. Additionally, the concern over dilution risk further exacerbates the potential for negative financial implications, creating uncertainty about the company's future capital structure and shareholder value.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.